[Trial Data] REDEFINE 1 — what cagri adds on top of sema
REDEFINE 1 — what cagri adds on top of sema. It is the sort of thing everyone half-believes and nobody writes down. Asked a question here that turned out to be based on a mechanism confusion. Three people untangled it patiently. Bought small deliberately because the evidence base is thin. That felt like the only…
The engineering problem was duration: native amylin is short-acting and aggregation-prone. A long-acting analogue suitable for weekly administration is what makes the combination clinically interesting.
The tolerability tables were more informative than the headline numbers, which is usually the case and never how it gets summarised.
satiety signalling rather than incretin signalling
Careful — that is a dosing intuition carried over from another board and there is no basis for it here.
do not assume the dosing intuitions from the GLP-1 boards transfer
Carried an assumption over from the tirzepatide board and was corrected within an hour. Deserved.
Independent result added to the log. Thank you for paying for it — there are very few on this compound.
What does the tolerability table in that paper actually say?